Bharat Immunological & Biological Corporation Ltd
Incorporated in 1989, Bharat Immunological and Biologicals Corporation Ltd manufactures biotechnology-based pharmaceuticals.[1]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit |
Ratios
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
|---|---|---|---|---|
| Electricity Consumption Standard per Lakh Doses of OPV Units per Lakh Doses ・Standalone data |
|
|||
| Light Diesel Oil Used in Boilers Liters ・Standalone data |
||||
| Number of Revenue-Generating Segments Count ・Standalone data |
||||
| OPV Revenue Share % of total segment revenue ・Standalone data |
||||
| Total Electricity Purchased Units ・Standalone data |
||||
Extracted by Screener AI
Documents
Announcements
- Clarification sought from Bharat Immunologicals & Biologicals Corporation Ltd
-
Announcement under Regulation 30 (LODR)-Winding-up
- Government approved closure of BIBCOL under Department of Biotechnology control.
-
Board Meeting Intimation for Intimation Of Date Of Board Meeting On 16.08.2024 Under Regulation 29 Of SEBI'S LODR.
- Board meeting scheduled for August 16, 2024.
-
Board Meeting Intimation for Intimation Of Date Of Board Meeting On 08.03.2024 Under Regulation 29 Of SEBI'S LODR.
- Board meeting scheduled for March 8, 2024.
- Compliance Of Regulation 34 Of LODR 2015 And Submission Annual Report For 34Th Annual General Meeting Scheduled On 29.12.2023.
Annual reports
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
-
Annual Report 2011
from bse
-
Annual Report 2010
from bse
-
Annual Report 2009
from bse
-
Annual Report 2008
from bse
Business Overview:[1][2]
BIBCL is a Central Public Sector Unit, under the Department of Biotechnology, Ministry of Science & Technology, Government of India, undertaking. It was established as a Public Sector Unit to achieve the production and supply of high-quality polio vaccine. The company had captured 60% of the total market share and was among the top 20 Biotech companies in Indiain India. Currently, it manufactures and produces a range of pharmaceutical products such as:
a) Oral Polio Vaccines (OPV Vaccine)
b) Diarrhea Management Kits
c) BIB Sweet Tablets
d) Hepatitis B vaccine
e) Zinc Tablets, etc.
In FY16, the company switched over to bOPV from tOPV. To add in product line, the company diversified into plasma-derived medicines and the Oral Cholera Vaccine.